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Abstract
Objective: The knowledge about health status in adults with disorder of sex 
development (DSD) is scarce.
Design and methods: A cross-sectional observational study in 14 European tertiary 
centers recruited 1040 participants (717 females, 311 males, 12 others) with DSD. Mean 
age was 32.4 ± 13.6 year (range 16–75). The cohort was divided into: Turner (n = 301), 
Klinefelter (n = 224), XY-DSD (n = 222), XX-DSD (excluding congenital adrenal hyperplasia 
(CAH) and 46,XX males) (n = 21), 46,XX-CAH (n = 226) and 45,X/46,XY (n = 45). Perceived 
and objective health statuses were measured and compared to European control data.
Results: In DSD, fair to very good general health was reported by 91.4% and only 8.6% 
reported (very) bad general health (controls 94.0% and 6.0%, P < 0.0001). Longstanding 
health issues other than DSD and feeling limited in daily life were reported in 51.0% 
and 38.6%, respectively (controls 24.5% and 13.8%, P < 0.0001 both). Any disorder 
except DSD was present in 84.3% (controls 24.6%, P < 0.0001). Males reported worse 
health than females. In the subgroup analysis, Klinefelter and 46,XX-DSD patients 
reported bad general health in 15.7% and 16.7%, respectively (Turner 3.2% and CAH 
7.4%). Comorbidities were prevalent in all DSD subgroups but Klinefelter and Turner 
were most affected. Early diagnosis of DSD and a healthy lifestyle were associated with 
less comorbidities.
Conclusions: Overall, general health appeared to be good but a number of medical 
problems were reported, especially in Klinefelter and Turner. Early diagnosis of DSD and 
a healthy lifestyle seemed to be important. Lifelong follow-up at specialized centers is 
necessary.
10.1530/EC-18-0031
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Introduction
Disorders of sex development (DSD) are characterized by 
incongruence of chromosomal, gonadal and genital sex 
development, and in some conditions, impaired adrenal 
function. DSD can be divided into three major groups: 
DSD with atypical sex chromosome configurations such 
as Turner syndrome (TS), Klinefelter syndrome (KS), 
45,X/46,XY and 46,XX/46,XY; XY-DSD characterized 
by impairment of testicular development, androgen 
biosynthesis or action or severe hypospadias of unknown 
origin; and XX-DSD characterized by androgen excess 
such as congenital adrenal hyperplasia (CAH) (1). Due 
to the wide range of pathophysiology and presentation, 
patients with DSD may need a large variety of treatments 
such as genital surgery, sex hormone replacement, 
glucocorticoid supplementation and other treatments, 
which beside the underlying cause also may affect the 
health status, both somatically and mentally. However, 
knowledge about the health status in individuals with 
DSD, especially adults, is scarce. For example, for the 
rare XY-DSD conditions, almost no data on health status 
are available except that there is a high prevalence of 
decreased bone mineral density in CAIS women (2, 3). 
The vast majority of reports have been published on the 
three larger groups of DSD, namely TS, KS and CAH. 
These reports have indicated increased risks of congenital 
abnormalities in TS, cardiometabolic risk factors and 
diseases mostly related to treatment, autoimmune 
disorders, tumors and psychiatric disorders in addition to 
decreased bone health with increased fracture incidence 
for all groups (4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 
17, 18, 19, 20, 21). A healthy lifestyle can modify and 
prevent many of these comorbidities but how the persons 
with DSD perceive their general health may differ from 
the perception of their treating physicians. Moreover, 
it could be speculated that a late diagnosis of DSD may 
result in a more compromised health status. Undiagnosed 
low sex hormone levels during adolescence may affect 
peak bone mass (3), while high androgen levels may 
affect voice and insulin sensitivity in females (22). Thus, 
more data on the health status in individuals with a DSD 
are needed, including modifying factors, to be able to 
predict, prevent and manage different health outcomes, 
in addition to plan specialized services for this group of 
patients.
The aim of this study was to describe the health status 
of the whole dsd-LIFE cohort by evaluating comorbidities, 
cardiovascular and metabolic risk factors, healthy lifestyle 
and age at diagnosis.
Subjects and methods
This study is part of the dsd-LIFE study (23). Patients, aged 
16  years and older with a medically confirmed clinical 
and/or genetic diagnosis of DSD, were recruited from 
14 sites, including Berlin, Munich, Lubeck and Munster 
(Germany); Paris, Lyon, Montpellier and Toulouse 
(France); Amsterdam and Nijmegen (The Netherlands); 
Lodz and Warsaw (Poland); Stockholm (Sweden) and 
Birmingham (UK). Control data were obtained from 
Eurostat (total n > 200,000; females n > 100,000; males 
n > 100,000, year 2014) (http://ec.europa.eu/eurostat/
web/health/overview), except in five conditions where 
no data were available, i.e., psychiatric disorders, suicide 
attempts, hypertension, dyslipidaemia and autoimmune 
disorders (only thyroid disorders) where controls were 
obtained from Swedish CAH studies with similar age and 
gender distribution as the dsd-LIFE study (total n = 58,800; 
females n = 33,500; males n = 25,300) (16, 18, 24).
Study protocol
The complete study protocol has been published in 
detail previously by Röhle et  al. (23). In summary, 
subjects underwent a medical examination, including 
questions about the medical history and answered 
a patient reported outcome questionnaire. The 
participation rate was 36.1% of those contacted, the 
genetic diagnosis rate was 78.6% of the total and 55.6% 
of those with non-sex chromosome DSD, the patient 
reported outcome questionnaire response rate was 
95.5%, medical history was supplied by 99.5% and 
examination was done in 89.2%. Data were entered 
anonymously into a database. Healthy lifestyle, age 
at diagnosis, cardiovascular and metabolic risk factors 
and comorbidity were evaluated. A healthy lifestyle was 
defined as never smoked in combination with sport 
activities ≥2 h/week. Participants were asked to rate 
their general health as good/very good, fair or bad/very 
bad. For cardiovascular and metabolic risk factors, the 
following variables were evaluated: body mass index 
(BMI) (overweight 25–29.9 and obesity ≥30 kg/m2); 
waist/hip ratio (central obesity ≥0.8 in females and ≥0.9 
in males, respectively); hypertension (blood pressure 
>140/90 mmHg); type 2 diabetes; dyslipidaemia and 
cardiovascular disease (history of heart attack, stroke, 
venous thromboembolism, arrhythmias, coarctation 
of the aorta, bicuspid aortic valve or aortic stenosis). 
For the description of comorbidities, the following 
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variables were used: psychiatric disorders (eating 
disorder, chronic anxiety, chronic depression, attention 
problems, hyperactivity, eruptive/aggressive behaviour, 
burn-out-syndrome, schizophrenia, autism, Asperger or 
pervasive developmental disorder, other mental health 
problems and/or suicide attempt); gastrointestinal 
disorders (fatty liver disease, hepatitis, elevated liver 
enzymes, Crohn’s disease/colitis and/or celiac disease); 
autoimmune disorders (Hashimoto’s thyroiditis, type 1 
diabetes, rheumatology disease, Crohn’s disease/colitis, 
celiac disease, allergies and/or asthma); joint problems 
(rheumatic disease and/or other joint problems); renal 
disorders (horseshoe kidney and/or renal insufficiency); 
malignancy; visual and hearing issues; neurological 
disorders (seizures and/or migraine); urinary issues 
(urinary tract infections and/or incontinence) and any 
disorder except DSD was defined as any of the disorders 
or problems above (except overweight and obesity), 
calculated with both visual issues included and excluded.
The study was approved by the Local Ethical Review 
Board at each participating center, and informed consent 
was obtained (23).
Statistical analysis
Mean ± s.d. or median (range) is reported for continuous 
variables, and absolute and relative frequencies for 
categorical outcomes. All proportions were calculated 
discounting missing values. Continuous variables were 
compared using t-tests, and categorical parameters were 
compared using chi-squared tests or Fisher exact tests, 
whichever most appropriate. Logistic regression models 
were used to explore the associations between different 
outcomes and age at diagnosis and healthy lifestyle. 
When odds ratios (ORs) were calculated, 95% confidence 
intervals (CIs) were reported. Due to the exploratory nature 
of dsd-LIFE, no adjustments for multiple comparisons 
were done. R (version 3.2.2) and SAS (version 9.4) were 
used for all statistical analyses.
Results
The results are shown in detail for the total cohort and 
for phenotypic females and males in Tables  1 and 2, 
broken down by subgroup in Tables 3 and 4 and logistic 
regression models in Table 5. In Supplementary Table 1 
(see section on supplementary data given at the end of 
this article), the number of individuals for each variable 
is shown.
Basic characteristics of the patients
In total, 1161 patients were evaluated in dsd-LIFE cohort, 
but males with CAH (n = 121) were excluded in the present 
analyses since they did not fulfill the complete criteria for 
a DSD diagnosis (23). Thus, 1040 patients were included 
with a mean age range of 32.4 ± 13.6 years. The different 
DSD diagnoses and the six major subgroups of the cohort 
are described in Table  1. One 47,XYY male was not 
included in any of the subgroups. The number of females 
was more than twice the number of males and the mean 
age about 4 years younger in females. Moreover, the mean 
age at diagnosis of the DSD condition was 8 years earlier 
in females (Table 2).
Lifestyle and general health
Around 15% in the whole DSD cohort was currently 
smoking, which was less than controls (Table  2). None 
of the XX-DSD individuals and only around 7% of 
individuals with TS or 45,X/46,XY smoked (Table  3). 
Sport activities per week, varied in the different groups 
and differed from controls. Especially the XY-DSD males 
seemed to be very active (Table 4). Of the entire cohort 
91.4% reported a fair to good/very good general health 
and only 8.6% reported bad or very bad general health, 
which was worse compared to controls. Males with DSD 
reported worse health compared to females with DSD 
(15.2% vs 5.6%). General health was worse compared 
to controls in all subgroups except in XY-DSD females, 
XX-DSD and 45,X/46XY. Longstanding health issues other 
than the DSD diagnosis were reported in about half the 
cohort with physical issues being most common. This was 
more than that in controls in all groups except XY-DSD 
males and XX-DSD. In general, males had more physical 
and psychiatric problems than females. Individuals with 
KS reported most longstanding health problems (62.4%). 
Almost half of all males felt limited in their daily life by 
health issues and the KS group was the subgroup that 
experienced the most limitations while only around 
14% of controls reported limitations. The composite 
endpoint ‘Any disorder except DSD’ was present in 84.3% 
of all cases, and in 94.5% of individuals with TS. Similar 
percentages were found when visual issues were excluded. 
This was 2–3 times more than those in controls.
Cardiovascular and metabolic disorders
Mean BMI was 25.5 kg/m2 in the entire cohort and 17.2% 
were obese (controls 14.8%). Males were more often 
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overweight and almost 60% of KS patients were either 
overweight or obese (male controls 54.8%) (Tables 2 and 3). 
More than 50% of the CAH patients were overweight or 
obese (38.8% female controls). However, the proportion 
of individuals with underweight (BMI <20 kg/m2) was also 
higher in the DSD groups compared to controls. Using 
the different waist/hip ratio cut-off levels for females and 
males indicated that the health risk in females with DSD 
was higher, especially in the XX-DSD subgroup. Type 2 
diabetes was present in 4.1% of all patients and was more 
prevalent in the male group (6.9%), which was higher 
than that in controls (1.7%). There were large differences 
Table 1 The specific diagnoses of the 1040 patients with DSD, their subgroup classification and sex.
Females Males Other Total
Turner syndrome 301
Monosomy: 45,X 150
Mosaics: 45,X/46,XX 31
Isochromosomes: 45,X/46,X,i(Xq)|46X,i(Xq)|45,X/46,X,i(Xq)/47,X,i(Xq) 59
Deletions: 45,X/46,X,del(X)|46,X,del(X) 19
Polyploidy: 45,X/46,XX/47,XXX|45,X/47,XXX|45,X/46,XX/47,XXX/48,XXXX 16
Ring material: 45,X/46,X,r(X) 12
Others and unknown 14
Klinefelter syndrome 224
47,XXY 1* 199 4
47,XXY/46,XY 5 1
47,XXY/46,XX 3
Others and unknown 5
46,XX testicular males 6
XY-DSD 222
Complete gonadal dysgenesis 20 1
Partial gonadal dysgenesis 12 25
XY ovotesticular DSD 3 2
CAIS 69 2
PAIS 17 18
3β-HSD deficiency 1 1
17β-HSD deficiency 9 2
5α-reductase deficiency 2 1 1
17α-hydroxylase/17,20 lyase deficiency 1
Unknown steroid synthesis defect with adrenal insufficiency 1
Unknown androgen synthesis defect 1
Hypospadias 24 1
Others and unknown 7 1
XX-DSD 21
XX gonadal dysgenesis 20
XX ovotesticular DSD 1
CAH 226
Salt-wasting 21OHD*** 109 2**
Simple virilising 21OHD*** 65 1**
Non-classical 21OHD*** 33 1**
Unknown phenotype 21OHD 3
STAR 1
3β-HSD deficiency 2
11β-hydroxylase deficiency 5 1**
POR deficiency 2
Unknown 1
45,X/46,XY 31 14 45
47,XYY with gonadal dysgenesis 1 1
Total 717 311 12 1040
Males with 46,XY-CAH were excluded (n = 121) since they did not fulfil all criteria of DSD. STAR, CAH caused by mutations in the steroidogenic acute 
regulatory protein gene, i.e., congenital lipoid adrenal hyperplasia.
*Had sex reassignment in adulthood; **46,XX; ***Mainly based on the predicted phenotype from genotype data.
21OHD, 21-hydroxylase deficiency; CAH, congenital adrenal hyperplasia; CAIS, complete androgen insensitivity syndrome; HSD, hydroxysteroid 
dehydrogenase; PAIS, partial androgen insensitivity syndrome; POR, cytochrome P450 oxidoreductase.
This work is licensed under a Creative Commons 
Attribution-NonCommercial 4.0 International 
License.
https://doi.org/10.1530/EC-18-0031
http://www.endocrineconnections.org © 2018 The authors
Published by Bioscientifica Ltd
H Falhammar et al. Health status in DSD 4707:3
in the prevalence of type 2 diabetes between the subgroups 
with 9.1% affected in the KS and only 1.5% in the XY-DSD 
subgroup. Hypertension was more prevalent compared 
to controls except in the XY-DSD female and XX-DSD 
groups. Dyslipidemia was more common compared to 
controls in all groups except in the XX-DSD. Dyslipidemia 
was especially prevalent in individuals with KS (19.9%). 
Around 15% of DSD had at least one cardiovascular 
disease (controls 5%), 3.1% two and 0.8% had three or 
more diagnoses with no differences between females 
and males. In the subgroups, cardiovascular disease was 
especially prevalent in the TS group, 45,X/46,XY and KS 
groups; however, the only subgroup with no increase 
compared to controls were phenotypically females with 
XY-DSD or XX-DSD.
Other comorbidity
Psychiatric disorders were reported in 45.2% and suicide 
attempt in 6.8% of all individuals with DSD and more 
males than females were affected (Table  2). Especially 
individuals with KS were affected, but all groups were 
more affected compared to controls (Tables  3 and 4). 
The prevalence of osteoporosis and fractures were 
similar between females and males, however, also here, 
individuals with KS were most affected. Gastrointestinal 
disorders were more prevalent in females with DSD 
overall and in TS (more compared to controls in most 
groups). Autoimmune disorders were present in a third 
of the entire DSD cohort (TS 45.2% and KS 43.3%) and 
equally common in both females and males, which was 
more than those in controls. Joint problems were more 
common in males with DSD overall and in KS. Renal 
disorders were most prevalent in females with DSD 
overall and in TS, mainly due to congenital horseshoe 
kidney in the latter. Malignancy had occurred in 4.1% 
and was more common than in controls in all groups 
except XY-DSD males, XX-DSD and 45,X/46,XY. Visual 
and hearing issues were prevalent, and most affected 
were patients with TS. Neurological disorders, i.e., 
seizures and/or migraine were most frequent in KS. 
Urinary issues were not different between the sexes, but 
XY-DSD and CAH were the most affected subgroups (no 
control data).
Logistic regression models
Using logistic regression models, there were significant 
associations between any long-standing health problem, 
health issues that limited daily life, any disorder except 
DSD and age at diagnosis of the DSD (Table  5). Similar 
relationships were also found with healthy lifestyle. There 
was only a tendency for obesity and age at diagnosis 
but an association was found with healthy lifestyle (OR 
0.32). However, there was a positive correlation with 
age at diagnosis and BMI (R = 0.03 per year, P < 0.0001). 
Type 2 diabetes, hypertension and dyslipidemia were 
associated with the age at diagnosis (OR 1.05, 1.03 and 
1.04, respectively). Thus, a diagnosis of DSD at 10 years 
or 40 years compared to at birth increased the odds for 
type 2 diabetes with 63% (OR 1.63) and 604% (OR 7.04), 
respectively. Type 2 diabetes and dyslipidemia were less 
common with a healthy lifestyle (OR 0.20 and 0.62, 
respectively). Cardiovascular disease was associated with 
the age at diagnosis (OR 1.03) but not healthy lifestyle. 
Psychiatric, autoimmune and neurological disorders (OR 
1.02, 1.02 and 1.03, respectively), joint and urinary issues 
(OR 1.03 and 0.96, respectively) were all associated with 
age at diagnosis. Among these disorders, healthy lifestyle 
was only associated with psychiatric disorders (OR 0.29). 
Similar results were found for the different subgroups and 
age at diagnosis and healthy lifestyle, respectively, but 
mostly not significant (data not shown). However, there 
was a relationship between age at diagnosis and age at 
inclusion in dsd-LIFE (Fig.  1) explaining some (28.8%) 
but not all outcomes related to age at diagnosis (R = 0.537, 
P < 0.0001).
Discussion
This is by far the largest study examining the health status 
in individuals diagnosed with DSD but also the first to 
include the majority of conditions encompassed by the 
DSD classification. The patients reported a good or fair 
general health in more than 91% of the cases and less 
than 9% reported bad or very bad general health. In 
general, males reported worse health than females but 
both males and females reported poorer health compared 
to European control data. Longstanding health issues 
other than DSD were reported by half of the individuals 
with men more often reporting both physical and 
psychiatric comorbidities compared to women. However, 
if all the different disorders, other than DSD, reported by 
the individuals themselves or the examining physicians 
were assessed together more than 80% had at least one 
additional comorbidity, which was 2–3 times more 
common than for controls. Thus, individuals with DSD 
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did not consider many of their comorbidities as major 
concerns. The finding that less than 40% responded that 
health issues had limited their daily life also supports this 
conclusion.
Cardiovascular and metabolic disorders were 
common in our cohort, which have previously been 
shown separately in TS, KS and CAH (5, 7, 16). It has 
been suggested that TS is an independent risk factor for 
cardiovascular disease leading to congenital heart disease, 
aortic dilation and dissection, valvular heart disease, 
hypertension, thromboembolism, myocardial infarction 
and stroke (5). Even though TS had the highest frequency 
of cardiovascular disease in our study, the frequency was 
almost as high in the group of 45,X/46,XY followed by 
the KS group. However, women with TS are often affected 
by congenital heart disease not seen in, e.g., KS and CAH 
(7, 16). A study of 16 children with 45,X/46,XY found 
increased risk of cardiac anomalies and other features of TS, 
and thus, recommended that 45,X/46,XY patients should 
have similar follow-up (25). However, our study suggests 
that all different DSD variants (except XY-DSD females 
and XX-DSD) may have increased cardiometabolic issues 
to some degree and should be monitored and treated 
accordingly.
Psychiatric disorders were prevalent, especially in 
KS. Similar rates have previously been reported in KS (7) 
and increased rates, however, not as high as in this study 
have also been reported in CAH (18, 24). The high rate 
of suicide attempts is of great concern. Moreover, some 
individuals (3.9%) preferred not to answer this question, 
which may for some, reflect that they had made a suicide 
attempt previously but did not want to disclose this or 
that they had had suicidal thoughts. Suicide and attempts 
have hardly been studied previously in DSD. In a Swedish 
registry study, females with CAH had a lower suicidal 
rate than the controls (0.9% vs 2%) (18), while in males 
with CAH, the rate was higher than in controls (2.8% vs 
1.2%) (24), thus, much lower than the 6% found among 
the individuals with CAH in the present study. Probably 
this reflects that the current study reports on self-reported 
suicidality while the previous registry studies gave 
diagnosis rates.
Reported osteoporosis and fractures were rather 
common despite the young age of the cohort. Especially 
individuals with TS and KS were affected, which has 
previously been attributed mainly to hypogonadism 
and also to X-chromosome abnormalities (4, 7). This 
needs to be investigated in more detail in future studies. 
In CAH, the use of glucocorticoids may further increase 
the risk (22), but in the present study, individuals with 
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CAH were least affected by osteoporosis. However, 
the fracture rate in CAH was three times higher than 
the osteoporosis rate. A similar pattern has been seen 
before in females with CAH (9) and may be due to 
their interest in rough sport and outdoor activities 
(26). Since most studies of bone mineral density and 
fractures in different variants of DSD have occurred in 
young individuals, it can be predicted that this will be 
an increasing issue with age.
There have been concerns about tumor risk in 
DSD, especially increased risk for germ cell tumors if 
Y-chromosome material is present (however not in KS) 
(27); breast and lung cancer in addition to non-Hodgkin 
lymphoma in KS (7, 27); meningioma and childhood 
brain tumors and possibly bladder cancer, melanoma 
and corpus uteri cancer in TS (6). We found an increased 
risk of malignancies. Since some of the gonads may have 
been removed during early childhood, the patient and 
physician may not be aware of the histological report; this 
may be an underestimation.
Most of the other results concerning comorbidities 
were as expected, for example, an increased risk of 
gastrointestinal and autoimmune disorders, horseshoe 
kidneys, visual and hearing issues in TS (5) and many 
of the individuals in the XY-DSD and CAH groups had 
had previous genital surgery and had more urinary 
issues. Neurological disorders (mainly migraine) and 
joint problems were especially prevalent in KS but also 
generally in the whole cohort compared to controls.
In particular, in our cohort, the patients with KS 
reported the worst outcome. They frequently reported 
bad general health and longstanding health problems, 
including most comorbidities. It is not uncommon that 
KS is undiagnosed, in an epidemiological study, only 
25% of the expected number of patients was diagnosed, 
and few were diagnosed before puberty (28). This could 
imply that the identified patients may be those that are 
more affected by their disorder or have contracted other 
disorders or comorbidities. Hence, there is a risk for a 
selection bias and overrepresentation of individuals with 
KS with more somatic and psychiatric difficulties in this 
study. On the other hand, a late diagnosis of KS could 
also at least partly explain the impaired health status 
vide infra. Interestingly, women with TS had also many 
disorders such as cardiovascular disorders, renal disorders, 
in particular horse kidneys and gastrointestinal disorders, 
i.e. celiac disease, known features of the syndrome, but 
they still reported better general health, less general 
health issues and limitations by the disorder than did 
individuals with KS.Vi
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The individuals that reported a healthy lifestyle 
had a reduced risk of developing psychiatric disorders 
and also as expected a reduced risk of obesity, type 2 
diabetes and dyslipidemia. However, a diagnosis of DSD 
at an older age was associated with an increase of most 
health issues. There was also a relationship between age 
Table 4 Characteristics and health status in the individuals diagnosed with XY DSD divided into phenotypical females and males 
compared to controls.
 Female XY DSD 
(n = 142)
Female controls€ 
(n > 100000)
 
P-value
Male XY DSD 
(n = 73)
Male controls€ 
(n > 100000)
 
P-value
Age (years) 30.7 ± 12.5 16–64 23.3 ± 7.7 16–64
Age at diagnosis (years) 13 (0–61) 0 (0–23)
Smoking 20.8% 18.5% 0.482 7.7% 26.2% 0.0003
Sports activities (cycling, swimming etc) 0.0021 0.0067
<2 h/week 40.5% 47.7% 30.2% 41.6%
2 h/week 16.5% 23.5% 12.7% 20.5%
>2 h/week 43.0% 28.7% 57.1% 37.9%
How is your health in general? 0.1729 <0.0001
  Very good/Good 68.6% 74.9% 54.4% 78.1%
  Fair 25.0% 18.9% 27.9% 16.1%
  Bad/Very bad 6.4% 6.2% 17.6% 5.8%
Longstanding health problem?* 35.3% 26.0% 0.0173 29.7% 23.0% 0.2333
  Physical? 90.0% 87.4%
  Psychiatric? 27.5% 43.7%
  Both? 17.5% 31.2%
Health issues limited daily life, past 6 m 32.3% 15.0% <0.0001 33.3% 12.5% <0.0001
BMI (kg/m2) 24.0 ± 6.5 24.4 ± 5.3
<20 kg/m2 28.2% 4.6% <0.0001 20.9% 1.7% <0.0001
20–24.9 kg/m2 40.5% 56.5% 44.8% 43.5%
25–29.9 kg/m2 21.4% 25.2% 19.4% 40.0%
≥30 kg/m2 9.9% 13.6% 14.9% 14.8%
W/H ratio 0.81 ± 0.13 0.79 ± 0.11
W/H ratio >0.8 (F) >0.9 (M) 36.1% 13.6%
Type 2 diabetes 1.5% 1.5% 0.7225 1.5% 1.9% 1
Hypertension 3.1% 1.7% 0.2889 9.0% 1.9% 0.0018
Dyslipidaemia 5.5% 0.3% <0.0001 3.0% 0.5% 0.0439
CV disease 6.3% 4.8% 0.2115 13.6% 5.2% 0.0021
CV diseases ≥2 0.8% 1.5%
CV diseases ≥3 0% 0%
Psychiatric dis 44.3% 11.2% <0.0001 37.7% 9.8% <0.0001
Suicide attempt 7.9% 2.0% 0.0001 5.9% 1.1% 0.0063
Prefer not to answer 2.9% 2.9%
Osteoporosis 9.8% 0%
Fractures 13.8% 4.5%
GI disorders 3.1% 2.0%** 0.3269 1.5% 2.0%** 1
Autoimmune dis 28.6% 1.7% <0.0001 20.9% 0.3% <0.0001
Joint problems 7.7% 8.4% 0.8752 0% 6.7% 0.023
Renal dis 0.8% 2.0%** 0.5266 0% 2.0%** 0.6466
Malignancy 3.1% 0.8% 0.0207 1.5% 0.5% 0.2857
Visual issues 23.6% 2.1% <0.0001 15.2% 1.8% <0.0001
Hearing issues 2.3% 1.0% 0.1379 4.5% 1.3% 0.0551
Neuro dis*** 18.8% 2.8% <0.0001 3.0% 1.3% 0.2121
Urinary issues 22.0% 25.4%
Any disorder* 77.5% 26.0% <0.0001 67.2% 23.1% <0.0001
Mean ± s.d. is given. Bold indicates P < 0.05.
*Except the DSD; **In controls this is the percentage of combined gastrointestinal and renal disorders; ***Neurological disorders in this case seizures 
and/or migraine. €Control data were from Eurostat (females n > 100,000; males n > 100,000) (http://ec.europa.eu/eurostat/web/health/overview), except in 
five conditions where no data were available, i.e., psychiatric disorders, suicide attempts, hypertension, dyslipidaemia and autoimmune disorders (only 
thyroid disorders) where controls were from Swedish CAH studies with similar age and gender distribution as the dsd-Life study (total n = 58,800; females 
n = 33,500; males n = 25,300) (18, 20, 26).
CV, cardiovascular; dis, disorders; GI, gastrointestinal; W/H, waist/hip.
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at diagnosis of DSD and age at inclusion in the study, 
but this could only explain a third of the increased 
risks. A late diagnosis could perhaps be explained by 
some presenting with their complications and the DSD 
diagnosis was made simultaneously. The increased risk of 
different comorbidities with age at diagnosis persisted, 
however, mostly non-significant when analyzed in 
the subgroups probably due to the smaller number 
of individuals. To be diagnosed as early as possible is 
important in order for management and information 
to be commenced promptly. This may reduce the risk 
of future comorbidities. Neonatal screening has already 
been implemented for CAH in many countries (29) and 
has been suggested for KS (7). Future studies have to 
explore if more diagnoses should be included into the 
neonatal screening programs.
This study has several limitations. Even though we 
were able to recruit a large number of participants, most 
were individuals with TS, KS or CAH while it was more 
difficult to include participants with XY-DSD conditions, 
partly because those conditions are rarer. There may 
also have been a selection bias since the participating 
centers represented many of the most specialized ones 
in Europe. The questionnaires were constructed in 
such a way that details of the co-morbidities may not 
have been captured. There was missing data since the 
participants could choose not to answer a question 
or do an examination. Controls were not recruited at 
the participating centers but large control data were 
obtained from Eurostat and previous published studies 
with similar ages, however, not exactly the same age, 
time period and geographical areas. However, the 
strengths of this study were that we were able to recruit 
the highest number of individuals with DSD so far, 
including some rare variants, and many perspectives of 
health were examined.
In conclusion, general health seemed good overall in 
individuals with DSD. However, many medical problems 
were reported, especially in KS, with a clear increased 
risk for both somatic and psychiatric morbidities in 
individuals who were diagnosed later. Knowledge on the 
specific health issues that might occur in the different 
diagnoses should be included in the patient education 
programs, especially during transition. The DSD expert 
centers have to tailor follow-up programs according to 
the needs of the individuals and the different diagnostic 
groups. Therefore, lifelong follow-up by multidisciplinary 
teams is necessary.
Table 5 Logistic regression models exploring associations between different outcomes and age at diagnosis and healthy lifestyle 
(never smoked and sports activities ≥2 h/week) in patients with DSD.
 Age at diagnosis Healthy lifestyle
OR (95% CI) P value OR (95% CI) P value
Longstanding health problem?* 1.04 (1.02–1.05) <0.0001 0.47 (0.20–1.09) 0.0853
Health issues limited daily life, past 6 m 1.04 (1.03–1.06) <0.0001 0.68 (0.29–1.61) 0.3702
Obesity 1.01 (1.00–1.03) 0.06782 0.32 (0.12–0.87) 0.0199
Type 2 diabetes 1.05 (1.03–1.08) 0.0002 0.20 (0.05–0.81) 0.0214
Hypertension 1.03 (1.02–1.04) 0.0003 0.71 (0.22–2.81) 0.8245
Dyslipidaemia 1.05 (1.02–1.07) <0.0001 0.62 (0.41–0.92) 0.0192
CV disease 1.03 (1.01–1.03) <0.0001 0.87 (0.58–1.27) 0.4728
Psychiatric disorders 1.02 (1.00–1.03) 0.0119 0.29 (0.12–0.66) 0.0033
Osteoporosis 1.06 (1.04–1.08) <0.0001 1.64 (0.39–11.39) 0.5460
Fractures 1.04 (1.02–1.05) <0.0001 0.80 (0.30–2.40) 0.6710
Autoimmune disorders 1.02 (1.01–1.03) 0.0064 1.08 (0.47–2.64) 0.9763
Joint problems 1.03 (1.01–1.05) 0.0046 0.85 (0.23–4.20) 0.7008
Visual issues 1.01 (1.00–1.03) 0.0565 5.69 (1.62–36.11) 0.0207
Hearing issues 1.01 (0.99–1.02) 0.2777 0.39 (0.16–1.00) 0.0469
Neurological disorders 1.02 (1.00–1.04) 0.0287 0.51 (0.16–2.00) 0.1153
Urinary issues 0.96 (0.94–0.98) 0.0006 0.55 (0.18–2.08) 0.3289
Any disorder* 1.04 (1.02–1.06) 0.0002 0.31 (0.07–0.93) 0.0003
The higher OR the higher risk per each year later the DSD diagnosis was made. Healthy lifestyle was compared to those with not having a healthy 
lifestyle. Bold indicates P < 0.05. No associations were found with waist/hip ratio, suicide attempts, renal and gastrointestinal disorders or malignancy 
(except females with age at diagnosis 1.04 (1.01–1.08), P = 0.0057) (not shown).
*Except the DSD.
CV, cardiovascular; OR, odds ratio.
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